U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 13 results

Status:
US Approved Rx (2010)
First approved in 1997

Class (Stereo):
CHEMICAL (ACHIRAL)



Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatm...
Status:
US Approved Rx (2018)
First approved in 1955

Class (Stereo):
CHEMICAL (RACEMIC)



Hydroxychloroquine possesses antimalarial properties and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. Although the exact mechanism of action is unknown, it may be base...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Loxoribine [RWJ 217C7] is an immunostimulant which was developed by Johnson and Johnson. It is a selective agonist for TLR7 (Toll-like receptor 7), which possesses antitumor and antiviral properties and was investigated in a rat model of endometriosi...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



CPG-52364 is a potent antagonist of toll-like receptors TLR7, TLR8, TLR9. The drug was developed by Coley Pharmaceutical Group (later acquired by Pfizer) for the treatment of immune diseases and reached phase I of clinical trials presumably for syste...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Vesatolimod, also known as GS-9620, is being developed in clinical studies for the treatment of chronic hepatitis B viral (HBV) infection, with the goal of inducing a liver-targeted antiviral effect without inducing the adverse effects associated wi...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Resiquimod is an imidazoquinolinamine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling pathway by binding to and activating TLR7 and 8 mainly on dendritic c...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)



6-amino-2-(butylamino)-9-((6-(2-(dimethylamino)ethoxy)pyridin-3-yl)methyl)-7,9-dihydro-8H-purin-8-one (DSR-6434) is a small molecule toll-like receptor (TLR)-7 agonist, which didn’t have direct antitumor activity, but enhanced efficacy of ionizing ra...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Gardiquimod, an imidazoquinoline compound, is a specific toll-like receptor 7 (TLR7) agonist. It acts as an immune response modifier and is a potential anticancer and antiviral agent. The core structure of gardiquimod is 1H-imidazo[4,5-c]quinoline li...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Bropirimine, an immunostimulating agent, and toll-like receptor (TLR7) agonist, with anti-cancer and antiviral properties. Bropirimine may be used in experimental autoimmune encephalomyelitis (EAE) and bladder cancer research. Bropirimine is an immun...
Status:
US Approved Rx (2018)
First approved in 1955

Class (Stereo):
CHEMICAL (RACEMIC)



Hydroxychloroquine possesses antimalarial properties and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. Although the exact mechanism of action is unknown, it may be base...

Showing 1 - 10 of 13 results